I
Isabelle Boucot
Researcher at GlaxoSmithKline
Publications - 51
Citations - 747
Isabelle Boucot is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Vilanterol & Medicine. The author has an hindex of 12, co-authored 44 publications receiving 567 citations.
Papers
More filters
Journal ArticleDOI
Patterns of systemic lupus erythematosus expression in Europe.
Ricard Cervera,Andrea Doria,Zahir Amoura,Munther A. Khamashta,Matthias Schneider,Francis Guillemin,Frédérique Maurel,A. Garofano,Montserrat Roset,A. Perna,M. Murray,Claude Schmitt,Isabelle Boucot +12 more
TL;DR: The disease was the most active in Black African descents, and this phenomenon has never been described before in continental Europe, and the disease was also more active in patients diagnosed at a younger or adult.
Journal ArticleDOI
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
François Maltais,Leif Bjermer,Edward Kerwin,Paul W. Jones,Michael L. Watkins,Lee Tombs,Ian Naya,Isabelle Boucot,David A. Lipson,Chris Compton,Mitra Vahdati-Bolouri,Claus Vogelmeier +11 more
TL;DR: Umeclidinium/vilanterol consistently provides early and sustained improvements in lung function and symptoms and reduces the risk of deterioration/treatment failure versus umeclinium or salmeterol in symptomatic patients with low exacerbation risk not receiving inhaled corticosteroids.
Journal ArticleDOI
Annual direct medical cost of active systemic lupus erythematosus in five European countries
Andrea Doria,Zahir Amoura,Ricard Cervera,Munther A Khamastha,Matthias Schneider,Jutta G Richter,Francis Guillemin,Gisela Kobelt,Frédérique Maurel,A. Garofano,A. Perna,Miranda Murray,Claude Schmitt,Isabelle Boucot +13 more
TL;DR: The annual direct medical cost of SLE patients in Europe is related to disease severity and flares, with each flare increasing the annual total cost by about €1002 (p<0.001).
Journal ArticleDOI
Defining the "Frequent Exacerbator" Phenotype in COPD: A Hypothesis-Free Approach.
Olivier Le Rouzic,Nicolas Roche,Alexis B. Cortot,Isabelle Tillie-Leblond,F. Masure,Thierry Perez,Isabelle Boucot,Latifa Hamouti,Juliette Ostinelli,Céline Pribil,Christine Poutchnine,Stéphane Schück,Mathilde Pouriel,Bruno Housset +13 more
TL;DR: Analysis of prospectively recorded exacerbations confirmed the existence and clinical relevance of a frequent exacerbator subgroup of patients with COPD and the currently used threshold to define this phenotype.
Journal Article
[The AIRE Study: data analysis of 753 European children with asthma].
TL;DR: In this article, analyser les donnees pediatriques de l'etude AIRE (Asthma Insights and Reality in Europe) decrivant le niveau de controle of l'asthme en Europe.